Scandion Oncology A/S Logo

Scandion Oncology A/S

SCOL | ST

Overview

Corporate Details

ISIN(s):
DK0061031895 (+3 more)
LEI:
549300MPWDMQ5LZEGD09
Country:
Denmark
Address:
Fruebjergvej 3, 2100 København Ø
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Scandion Oncology A/S is a company under liquidation. Previously, it operated as a clinical-stage biotechnology company focused on overcoming cancer drug resistance. The company's mission was to develop first-in-class, oral add-on drugs to revert resistance to existing cancer treatments and improve patient outcomes. Its primary development asset was the lead compound SCO-101, which aimed to enhance the efficacy of chemotherapy in patients who had developed treatment resistance. The company's research was centered on creating a pipeline of drugs targeting various molecular drug resistance mechanisms in cancer cells.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Scandion Oncology A/S. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Scandion Oncology A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Scandion Oncology A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Spago Nanomedical AB Logo
Develops nanomedicine for precision MRI tumor diagnostics and targeted cancer radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Developing first-in-class macrocyclic drugs for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops and out-licenses preclinical cancer drug programs using fragment-based discovery.
Sweden SPRINT
Stayble Therapeutics AB Logo
Develops an injectable therapy for disc-related spinal disorders as an alternative to surgery.
Sweden STABL
Stem Cells Spin Spolka Akcyjna Logo
Commercializes patented MIC-1 stem cell technology for regenerative medicine.
Poland SCS
STRIX GROUP PLC Logo Isle of Man KETL
SynAct Pharma Logo
Developing oral resolution therapies for inflammatory diseases like rheumatoid arthritis.
Sweden SYNACT
SYNAIRGEN PLC Logo
Develops an inhaled interferon beta therapy for severe viral lung infections.
United Kingdom SNG
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT
Israel TMIS